(VIANEWS) – The Market ended the session with PCI BIOTECH HOLD (PCIB.OL) rising 20.92% to kr2.37 on Tuesday while Oslo Børs Benchmark Index_GI rose 1.57% to kr1,245.08.
PCI BIOTECH HOLD’s last close was kr1.96, 67.11% below its 52-week high of kr5.96.
About PCI BIOTECH HOLD
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in pre-clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Olix Pharmaceuticals, Aposense, IMV Immunovaccine, MDimune, eTheRNA, and Immunicum. PCI Biotech Holding ASA was incorporated in 2007 and is based in Oslo, Norway.
Earnings Per Share
As for profitability, PCI BIOTECH HOLD has a trailing twelve months EPS of kr-1.02.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -53.97%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, PCI BIOTECH HOLD’s stock is considered to be oversold (<=20).
Yearly Top and Bottom Value
PCI BIOTECH HOLD’s stock is valued at kr2.37 at 22:37 EST, way below its 52-week high of kr5.96 and way above its 52-week low of kr1.52.
Volume
Today’s last reported volume for PCI BIOTECH HOLD is 332967 which is 378.86% above its average volume of 69533.
More news about PCI BIOTECH HOLD (PCIB.OL).
